Business
LARK: Gene therapy focus sharpened, COZY prioritized, and cost cuts extend liquidity to 2026
LARK: Gene therapy focus sharpened, COZY prioritized, and cost cuts extend liquidity to 2026
About this update from Larkberget Ab
Sharpened focus on gene therapy led to the termination of CG01 and CGT2, with all R&D now directed to the COZY program. Cost reductions extend liquidity to Q2 2026, while financials reflect lower revenue and continued operating losses.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.